Abstract:Ischemic stroke, as a prevalent neurological disorder, often results in rapid increases in the production of reactive oxygen species (ROS) and inflammatory factors in the focal ischemic area. Though edaravone is an approved treatment, its effect is limited due to its weak ability to cross the blood-brain barrier (BBB) and short half-life. Other effective pharmacological treatment options are clearly lacking. In this study, PNIVDBrF-3-Eda (also named MG-3-Eda) was prepared using a thermo- and pH dual-responsive PNIVDBrF microgel. These were designed with a positively charged network, as synthesized by simultaneous quaternization cross-linking and surfactant-free emulsion copolymerization, to be loaded with the negatively charged edaravone. We then investigated whether such a targeted delivery of edaravone could provide enhanced neuroprotection. Cytotoxicity assays confirmed that the microgel (<1 mg/mL) exhibited promising cytocompatibility with no remarkable effect on cell viability, cell cycle regulation, or apoptosis levels. In vitro and in vivo experiments demonstrated that the microgels could successfully penetrate the blood-brain barrier where efficient BBB crossing was observed after disruption of the BBB due to ischemic injury. This enabled MG-3-Eda to target the cerebral ischemic area and achieve local release of edaravone. Treatment with MG-3-Eda significantly reduced the cerebral infarct area in transient middle cerebral artery occlusion (tMCAO) mice and significantly improved behavioral scores. MG-3-Eda treatment also prevented the reduction in NF200 expression, a neuronal marker protein, and attenuated microglia activation (as detected by Iba1) in the local ischemic area via local antioxidant and anti-inflammatory effects. A superior neuroprotective effect was noted for MG-3-Eda compared to that for free edaravone. Our results indicate that MG-3-Eda administration represents a clear potential treatment for cerebral ischemia via its targeted delivery of edaravone to ischemic areas where it provides significant local antioxidant and anti-inflammatory effects.

Design, synthesis, and neuroprotective effects of novel hybrid compounds containing edaravone analogue and 3-<i>n</i>-butylphthalide ring-opened derivatives

Novel Hybrids of 3-N-butylphthalide and Edaravone: Design, Synthesis and Evaluations As Potential Anti-Ischemic Stroke Agents

Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

Novel Hybrids of 6-Amino-3-n-butylphthalide and Neuroprotective Groups against Ischemic Stroke

Novel Hybrids of Optically Active Ring-Opened 3-N-butylphthalide Derivative and Isosorbide As Potential Anti-Ischemic Stroke Agents.

Design, synthesis, and evaluation of n-butylphthalide and ligustrazine hybrids as potent neuroprotective agents for the treatment of ischemic stroke in vitro and in vivo

The Edaravone and 3-N-butylphthalide Ring-Opening Derivative 10b Effectively Attenuates Cerebral Ischemia Injury in Rats

Synthetic phenylethanoid glycoside derivatives as potent neuroprotective agents.

Design, Synthesis, and Biological Evaluation of Novel Cinnamide Derivatives as Neuroprotective Agents for the Treatment of Cerebral Ischemia

Novel 2,6-Disubstituted Benzofuran-3-one Analogues Improve Cerebral Ischemia/reperfusion Injury Via Neuroprotective and Antioxidative Effects.

Discovery of benzyloxy benzamide derivatives as potent neuroprotective agents against ischemic stroke

Synthesis and bioevaluation of Scutellarein-Tertramethylpyrazine hybrid molecules for the treatment of ischemic stroke

Design, Synthesis and Biological Evaluation of Tricyclic Diterpene Derivatives As Novel Neuroprotective Agents Against Ischemic Brain Injury.

Design and Synthesis of the Ring-Opened Derivative of 3-N-butylphthalide-ferulic Acid-Glucose Trihybrids As Potential Anti-Ischemic Agents

Discovery of novel danshensu derivatives bearing pyrazolone moiety as potential anti-ischemic stroke agents with antioxidant activity

Development of Novel N-hydroxypyridone Derivatives As Potential Anti-Ischemic Stroke Agents

Synthesis and Biological Evaluation of Hybrids from Optically Active Ring-Opened 3-N-butylphthalide Derivatives and 4-Fluro-edaravone As Potential Anti-Acute Ischemic Stroke Agents

Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents

Design, Synthesis, and Evaluation of NDGA Analogues As Potential Anti-Ischemic Stroke Agents.

A Comparative Study of the Neuroprotective Effects of Dl-3-n-butylphthalide and Edaravone Dexborneol on Cerebral Ischemic Stroke Rats

Synthesis and biological evaluation of aryloxyacetamide derivatives as neuroprotective agents.